Monash University, Melbourne, Australia.
Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):753-67. doi: 10.1016/j.beem.2009.06.004.
The combination of serum thyroid-stimulating hormone (TSH) with measurement of circulating thyroid hormones greatly improves sensitivity and specificity of thyroid diagnosis, but these assays are not impeccable. Estimation of serum free T4 conveniently accommodates variations in the concentration of thyroxine-binding globulin (TBG), but no current technique reliably reflects the in vivo free T4 concentration in numerous other situations. The effect of circulating competitors that increase T4 and T3 in vivo, in particular, many medications, is under-estimated by current free hormone estimates that involve sample dilution. Non-esterified fatty acids generated during sample storage and incubation can spuriously increase the measured free T4 estimate, especially after in vivo treatment with heparin. These artefacts are unlikely to be overcome by current assay strategies. Total serum T4, corrected for alterations in TBG concentration, gives a more robust estimate of thyroxine concentration than current methods of free hormone estimation and should now be reintroduced as the 'gold standard'.
血清促甲状腺激素(TSH)与循环甲状腺激素测量相结合极大地提高了甲状腺诊断的敏感性和特异性,但这些检测并非完美无缺。血清游离 T4 的估算方便地适应了甲状腺结合球蛋白(TBG)浓度的变化,但目前没有一种技术能够可靠地反映在许多其他情况下的体内游离 T4 浓度。目前涉及样本稀释的游离激素估算方法低估了体内循环竞争物对 T4 和 T3 的增加,特别是许多药物的影响。在样本储存和孵育过程中产生的非酯化脂肪酸会人为地增加测量的游离 T4 估算值,尤其是在体内用肝素治疗后。目前的检测策略不太可能克服这些人为因素。校正 TBG 浓度变化后的总血清 T4 比目前的游离激素估算方法更能准确估计甲状腺素浓度,现在应该重新作为“金标准”引入。